1ARENAS M D,ALVAREZ-UDE F, GIL M T, et al. Implemen- tation of K/DOQI clinical practice guidelines for bone metabo- lism and disease in chronic kidney disease' after the introduc- tion of cinacaleet in a population of patients on chronic haemodialysis [ J ]. Nephrol Dial Transplant, 2007, 22 ( 6 ) : 1639-1644.
2MALBERTI F, MARCELLI D, CONTE F, et al. Parathyroidec- tomy in patients on renal replacement therapy:an epidemiolog- ic study [J]. J Am Soc Nephrol,2001,12(6) :1242-1248.
3PULGAR B D, JARA C A, GONZALEZ V G, et al. Surgical treatment of renal hyperparathyroidism. Experience in 71 patients [ J ]. Rev Med Chile,201,143 (2) : 190-196.
4FAUL C, AMARAL A P, OSKOUEI B, et al. FGF23 induces left ventricular hypertrophy[ J]. J Clin Invest,2011,121 ( 11 ) : 4393-4408.
6DUNLAY R,RODRIGUEZ M,FELSENFELD A J,et al. Direct inhibitory effect of calcitriol on parathyroid function ( sigmoidal curve) in dialysis[ J]. Kidney Int, 1989,36(6) : 1093-1098.
8SPRAGUE S M, LLACH F, AMDAHL M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism [ J]. Kidney Int, 2003,63 ( 4 ) : 1483-1490.
9BLOCK G A,MARTIN K J,De FRANCISCO A L,et al. Cina- calcet for secondary hyperparathyroidism in patients receiving hemodialysis [ J]. N Engl J Med,2004,350( 15 ) : 1516-1525.
10LOCATELLI F, MESSA P, BELLASI A, et al. What can we learn from a statistically inconclusive trial? Consensus con- ference on the EVOLVE study results [ J ]. G Ital Nefrol, 2013,30(5). Pii: gin/30.5.4.
二级参考文献32
1Kidney Disease:Improving Global Outcomes(KDIGO)CKD-MBD fork Group.KDIGO clinical practice guideline for the diagnosis,evaluation,prevention,and treatment of Chronic Kidney Disease-Mineral and Bone Disorder(CKD-MBD)[J].Kidney Int Suppl,2009:S1-130.
2National Kidney Foundation.K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease[J].Am J Kidney Dis,2003,42:S1-201.
3Spasovski GB,Bervoets AR,Behets GJ,et al.Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis[J].Nephrol Dial Transplant,2003,18:1159-1166.
4Klawansky S,Komaroff E,Cavanaugh PF,Jr.,et al.Relationship between age,renal function and bone mineral density in the US population[J].Osteoporos Int,2003,14:570-576.
5Alem AM,Sherrard DJ,Gillen DL,et al.Increased risk of hip fracture among patients with end-stage renal disease[J].Kidney Int,2000,58:396-399.
6Jamal SA,Bauer DC,Ensrud KE,et al.Alendronate treatment in women with normal to severely impaired renal function:an analysis of the fracture intervention trial[J].J Bone Miner Res,2007,22:503-508.
7Miller PD,Roux C,Boonen S,et al.Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method:a pooled analysis of nine clinical trials[J].J Bone Miner Res,2005,20:2105-2115.
8Sprague SM,Belozeroff V,Danese MD,et al.Abnormal bone and mineral metabolism in kidney transplant patients-a review[J].Am J Nephrol,2008,28:246-253.
9Julian BA,Laskow DA,Dubovsky J,et al.Rapid loss of vertebral mineral density after renal transplantation[J].N Engl J Med,1991,325:544-550.
10Weisinger JR,Carlini RG,Rojas E,et al.Bone disease after renal transplantation[J].Clin J Am Soc Nephrol,2006,1:1300-1313.
